Published in Trends Mol Med on December 01, 2003
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 2.01
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood (2015) 1.48
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Bone marrow and the control of immunity. Cell Mol Immunol (2011) 1.15
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest (2014) 1.07
Cerebral ischemia increases bone marrow CD4+CD25+FoxP3+ regulatory T cells in mice via signals from sympathetic nervous system. Brain Behav Immun (2014) 0.88
T cell-expressed CD40L potentiates the bone anabolic activity of intermittent PTH treatment. J Bone Miner Res (2015) 0.81
Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation. Biol Blood Marrow Transplant (2010) 0.81
Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One (2010) 0.80
CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemia. Blood (2015) 0.78
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Oncoimmunology (2015) 0.77
A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). BMC Cancer (2015) 0.75
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care (Basel) (2016) 0.75
Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy. Front Immunol (2016) 0.75
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. Cancer Immunol Immunother (2017) 0.75
FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 9.24
Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity (2007) 5.67
Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med (2004) 5.08
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature (2012) 4.31
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science (2009) 3.47
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood (2005) 2.55
T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res (2009) 2.43
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res (2011) 2.08
Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res (2010) 2.07
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A (2011) 1.89
The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85
Origin of monocytes and macrophages in a committed progenitor. Nat Immunol (2013) 1.84
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 1.84
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol (2012) 1.62
Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res (2011) 1.61
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol (2012) 1.56
Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol (2011) 1.52
SPODOBASE: an EST database for the lepidopteran crop pest Spodoptera. BMC Bioinformatics (2006) 1.48
In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A (2010) 1.47
The significant role of mast cells in cancer. Cancer Metastasis Rev (2011) 1.42
Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med (2010) 1.41
High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res (2005) 1.35
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 1.28
Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity (2011) 1.23
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
The auditory sensitivity is increased in tinnitus ears. J Neurosci (2013) 1.22
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother (2011) 1.21
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol (2009) 1.20
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood (2004) 1.19
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest (2004) 1.16
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer (2013) 1.15
Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst (2007) 1.15
Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer (2012) 1.12
B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology (2013) 1.10
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol (2009) 1.08
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res (2009) 1.07
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest (2014) 1.07
Monocytes and macrophages in cancer: development and functions. Cancer Microenviron (2012) 1.06
Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol (2011) 1.04
The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res (2006) 1.02
Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res (2003) 1.02
Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol (2009) 1.00
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol (2013) 1.00
Thymic negative selection is functional in NOD mice. J Exp Med (2012) 1.00
Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer (2003) 1.00
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol (2012) 0.98
Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med (Berl) (2008) 0.98
Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res (2004) 0.97
Photoreceptor proteins as cancer-retina antigens. Int J Cancer (2007) 0.97
Densovirus infectious pathway requires clathrin-mediated endocytosis followed by trafficking to the nucleus. J Virol (2009) 0.97
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol (2008) 0.96
Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology (2005) 0.95
Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res (2006) 0.95
Dynamic differentiation of activated human peripheral blood CD8+ and CD4+ effector memory T cells. J Immunol (2005) 0.95
The same genomic region conditions clonal deletion and clonal deviation to the CD8alphaalpha and regulatory T cell lineages in NOD versus C57BL/6 mice. Proc Natl Acad Sci U S A (2007) 0.94
Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology (2009) 0.93
Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer (2014) 0.93
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol (2012) 0.93
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer (2003) 0.92
T cells as pioneers: antigen-specific T cells condition inflamed sites for high-rate antigen-non-specific effector cell recruitment. Immunology (2009) 0.92
Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. Cancer Immunol Immunother (2013) 0.92
Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer (2009) 0.91
PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer. Clin Cancer Res (2013) 0.91
Current developments with peptide-based human tumor vaccines. Curr Opin Oncol (2009) 0.91
Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. BMC Cancer (2013) 0.91
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Virus Res (2008) 0.91
Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction. J Mol Med (Berl) (2002) 0.89
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunol Immunother (2008) 0.89
Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett (2003) 0.89
Pathogenesis of Junonia coenia densovirus in Spodoptera frugiperda: a route of infection that leads to hypoxia. Virology (2010) 0.89
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol (2008) 0.89
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol (2007) 0.89
Skin-specific promoters for genetic immunisation by DNA electroporation. Vaccine (2009) 0.89
Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol Immunol (2009) 0.88
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines (2014) 0.88
Junonia coenia densovirus-based vectors for stable transgene expression in Sf9 cells: influence of the densovirus sequences on genomic integration. J Virol (2003) 0.87
A genomic BAC library and a new BAC-GFP vector to study the holocentric pest Spodoptera frugiperda. Insect Biochem Mol Biol (2004) 0.87
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology (2013) 0.87